Cargando…

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) were initially established as second- or third-line treatment of advanced non-small-cell lung cancer (NSCLC). Subsequent studies, including IPASS, OPTIMAL, and EURTAC, have demonstrated that these TKIs are effective first-line t...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Kim-Son H, Neal, Joel W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459550/
https://www.ncbi.nlm.nih.gov/pubmed/23055691
http://dx.doi.org/10.2147/BTT.S26558
_version_ 1782244819662274560
author Nguyen, Kim-Son H
Neal, Joel W
author_facet Nguyen, Kim-Son H
Neal, Joel W
author_sort Nguyen, Kim-Son H
collection PubMed
description Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) were initially established as second- or third-line treatment of advanced non-small-cell lung cancer (NSCLC). Subsequent studies, including IPASS, OPTIMAL, and EURTAC, have demonstrated that these TKIs are effective first-line therapeutic options in patients with tumors harboring activating mutations in the EGFR gene. The TKIs are better tolerated than conventional chemotherapy, with frequent yet mild side effects such as rash and diarrhea, and rarely interstitial lung disease. Because most patients on TKIs develop resistance due to a variety of mechanisms, the use of TKIs in the acquired-resistance setting and in the setting of earlier-staged cancers is being extensively studied. Here we review the major trials leading to the established use of EGFR TKIs in NSCLC, followed by discussion of recently completed and ongoing trials using the next-generation EGFR inhibitor afatinib.
format Online
Article
Text
id pubmed-3459550
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-34595502012-10-09 First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors Nguyen, Kim-Son H Neal, Joel W Biologics Review Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) were initially established as second- or third-line treatment of advanced non-small-cell lung cancer (NSCLC). Subsequent studies, including IPASS, OPTIMAL, and EURTAC, have demonstrated that these TKIs are effective first-line therapeutic options in patients with tumors harboring activating mutations in the EGFR gene. The TKIs are better tolerated than conventional chemotherapy, with frequent yet mild side effects such as rash and diarrhea, and rarely interstitial lung disease. Because most patients on TKIs develop resistance due to a variety of mechanisms, the use of TKIs in the acquired-resistance setting and in the setting of earlier-staged cancers is being extensively studied. Here we review the major trials leading to the established use of EGFR TKIs in NSCLC, followed by discussion of recently completed and ongoing trials using the next-generation EGFR inhibitor afatinib. Dove Medical Press 2012 2012-09-25 /pmc/articles/PMC3459550/ /pubmed/23055691 http://dx.doi.org/10.2147/BTT.S26558 Text en © 2012 Nguyen and Neal, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Nguyen, Kim-Son H
Neal, Joel W
First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
title First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
title_full First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
title_fullStr First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
title_full_unstemmed First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
title_short First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
title_sort first-line treatment of egfr-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459550/
https://www.ncbi.nlm.nih.gov/pubmed/23055691
http://dx.doi.org/10.2147/BTT.S26558
work_keys_str_mv AT nguyenkimsonh firstlinetreatmentofegfrmutantnonsmallcelllungcancertheroleoferlotinibandothertyrosinekinaseinhibitors
AT nealjoelw firstlinetreatmentofegfrmutantnonsmallcelllungcancertheroleoferlotinibandothertyrosinekinaseinhibitors